Drugs / QLH2405
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07489599 | Mar 2026 → Mar 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLH2405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07489599 ↗ |
| Route | Subcutaneous | “Single, Subcutaneous, Ascending Doses” NCT07489599 ↗ |